Drug intelligence / Profile preview

TUL321

Development stage: Phase 1
Lead developer: United Lab
Modality: Small Molecules
Administration: Oral

Overview

TUL321 is an orally bioavailable small molecule inhibitor of complement Factor B (CFB), developed by Zhuhai United Laboratories for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). By targeting Factor B, a key protease in the alternative complement pathway, TUL321 aims to prevent the formation of the C3 convertase, thereby inhibiting both intravascular and extravascular hemolysis. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and patients with PNH.

Targets

CFB (Complement Factor B)

Beyond the preview

Go deeper on TUL321.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TUL321.

Explore the full profile